Recent Quotes
My Watchlist
Indicators
Local Stocks
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Denali Therapeutics Inc (NQ: DNLI )

27.05 +0.71 (+2.68%)
Streaming Delayed Price Updated: 3:55 PM EDT, Sep 11, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Denali Therapeutics Inc

< Previous 1 2 3 4 Next >
Denali Therapeutics Breakthrough Blood-Brain Barrier Platform A Game-Changer in Neurodegenerative Diseases: Analyst
B Riley Securities initiated coverage on Denali Therapeutics Inc (NASDAQ: DNLI) with a Buy rating and a  
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 6, 2023
Via Benzinga
Analyst Expectations for Denali Therapeutics's Future
Via Benzinga
Where Denali Therapeutics Stands With Analysts
Via Benzinga
Analyst Expectations for Denali Therapeutics's Future
Within the last quarter, Denali Therapeutics (NASDAQ:DNLI) has observed the following analyst ratings: 
Via Benzinga
Why Shares of Denali Therapeutics Are Up Monday
Analysts maintained their buy ratings on the clinical-stage biotech company. 
Via The Motley Fool
Denali Therapeutics Announces New Interim Data from Phase 1/2 Study of DNL310 (ETV:IDS) in MPS II (Hunter Syndrome) at SSIEM 2023
From Denali Therapeutics Inc.
Via GlobeNewswire
Denali Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights
From Denali Therapeutics Inc.
Via GlobeNewswire
Cash In on the Longevity Boom: 3 Biotech Stocks to Buy Now
With longevity back in the news, many investors are wondering which biotech stocks to buy to best cash in on the growing trend. 
Via InvestorPlace
Where Denali Therapeutics Stands With Analysts
Via Benzinga
Where Denali Therapeutics Stands With Analysts
Via Benzinga
Expert Ratings for Denali Therapeutics
Via Benzinga
Denali Says Hunter Syndrome Candidate Lowers Disease-Associated Biomarker
Denali Therapeutics Inc (NASDAQ: DNLI) announced new interim results from the ongoing open-label, single-arm Phase 1/2 study of DNL310 IDS in children with  
Via Benzinga
Denali Therapeutics Announces Robust Reduction in Neurofilament Light (NfL) with DNL310 (ETV:IDS) Treatment in MPS II (Hunter Syndrome)
From Denali Therapeutics Inc.
Via GlobeNewswire
Biogen and Denali Realign Parkinson's Disease Research Priorities Amidst R&D Restructure
Via Benzinga
Analysts Say These 2 Mid-Cap Biotechs Have 2x Potential
These two mid-cap biotech companies are relatively established in their fields — but according to analysts, still have significant upside. 
Via MarketBeat
Exposures Product Safety
Denali Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights
From Denali Therapeutics Inc.
Via GlobeNewswire
Biogen Moves Deeper In Alzheimer's With Denali
Biogen exercised their rights to a Denali Alzheimer's drug. What does this mean longer term to the field and the companies? 
Via Talk Markets
Biogen Exercises Option with Denali to Develop and Commercialize Antibody Transport Vehicle Program Targeting Amyloid Beta
Program uses Denali’s Antibody Transport Vehicle (ATV) technology to cross the blood-brain barrier (BBB) and aims to increase target engagement 
From Denali Therapeutics Inc.
Via GlobeNewswire
Denali Therapeutics Announces New DNL343 (eIF2B Agonist) Phase 1b Data in ALS To Be Presented at the Upcoming AAN Annual Meeting
From Denali Therapeutics Inc.
Via GlobeNewswire
Denali Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights
From Denali Therapeutics Inc.
Via GlobeNewswire
Denali Therapeutics Reveals New Interim Data From Early-Stage Hunter Syndrome Study
Via Benzinga
Denali Therapeutics Announces New Interim Data from DNL310 Phase 1/2 Study for MPS II and DNL126 Preclinical Data for MPS IIIA at WORLDSymposium™
From Denali Therapeutics Inc.
Via GlobeNewswire
3 More Mid-Cap Biotechs The Street Sees Doubling
According to Wall Street research groups, these three mid-cap biotechs have 2x potential. It’s for the investor to decide if the upside justifies the risk. 
Via MarketBeat
Denali Therapeutics Announces Presentations on Enzyme Transport Vehicle (ETV) Development Programs for MPS Diseases at the Upcoming WORLDSymposium™
From Denali Therapeutics Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For January 30, 2023
Via Benzinga
Denali Therapeutics Announces Achievement of RIPK1 Milestone for Phase 2 Clinical Trial Initiation in Multiple Sclerosis by Sanofi
From Denali Therapeutics Inc.
Via GlobeNewswire
Denali Therapeutics Announces Key Anticipated 2023 Milestones for Its Therapeutic Portfolio for Neurodegeneration and Lysosomal Storage Diseases
From Denali Therapeutics Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For December 5, 2022
Via Benzinga
Denali Therapeutics Announces DNL343 Interim Phase 1b Data in ALS and Entry into the HEALEY ALS Platform Trial
From Denali Therapeutics Inc.
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.